Parlodel SRO in Parkinson's disease: a double-blind randomized comparison of Parlodel standard and Parlodel SRO.
In this study, we compared in an intent-to-treat analysis the tolerance and efficacy of Parlodel SRO with its standard galenic formulation in 34 patients with Parkinson's disease who received optimal levodopa therapy. The results suggest that Parlodel SRO was equally efficacious as Parlodel standard, but Parlodel SRO is better tolerated.
Jansen
E N
EN
Department of Neurology, Hospital Medisch Spectrum Twente, Enschede, The Netherlands.
Staal-Schreinemachers
A
A
van der Sande
J J
JJ
Haas
J A
JA
Lakke
J P
JP
D000284:Administration, Oral; D000368:Aged; D001971:Bromocriptine / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy*
D003692:Delayed-Action Preparations; D001971:Bromocriptine; D007980:Levodopa